A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 2
- 主要终点
- Number of participants with adverse events [Time Frame- ]
研究概览
简要总结
This is a Phase I clinical study of MSP008-22, the Investigational Medicinal Product (IMP). The current study is designed to evaluate the safety and tolerability and pharmacokinetics of single and multiple oral doses of the IMP (MSP008-22) in healthy volunteers.
详细描述
MSP008-22 is a New Chemical Entity (NCE) that has demonstrated positive outcomes during in vitro and in vivo studies for COVID19.
This clinical study is planned as a double blind, randomised, placebo-controlled, combined clinical study of two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies, respectively. Pharmacokinetic (PK) profile of the MSP008-22 will also be assessed in both parts of the study. The safety, tolerability and pharmacokinetic data and results obtained from this study will determine the potentially efficacious doses of the IMP (MSP008-22) in the subsequent efficacy studies in COVID-19 patients.
The SAD Part will consist of 6 cohorts of 8 healthy adult volunteers, each volunteer will be randomly (blinded) allocated to MSP008-22 or placebo (each cohort will consist of 6 volunteers receiving MSP008-22 and 2 volunteers receiving placebo). Six (6) dose levels (200 (OD), 400(OD), 400(BD), 600(BD), 800(BD) and 1000 (BD) mg) of MSP008-22 are selected for oral administration. An additional cohort of 8 volunteers (6:2 MSP008-22 vs placebo) of lower doses of MSP008-22 (less than 1000 mg BD) may be recruited into the SAD Part, if required.
The MAD Part will consist of 2 cohorts of 8 healthy adult volunteers, each volunteer will be randomly (blinded) allocated to MSP008-22 or placebo (each cohort will consist of 6 volunteers receiving MSP008-22 and 2 volunteers receiving placebo). Two (2) dose levels (800(BD) and 1000(BD) mg) of the MSP008-22 are selected for oral administration.
An additional cohort of 8 volunteers (6:2 MSP008-22 vs placebo) of lower doses of MSP008-22 (less than 1000 mg BD) may be recruited into the MAD Part, if required.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Both the Investigator and study participants will remain blinded to the treatment administered (drug or placebo) till the final results of the study are obtained.
The placebo will identical to the investigational medicinal product in smell, taste, and appearance.
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Volunteers will be enrolled in the study when the following inclusion criteria will be met:
- •Should be healthy adult volunteer in the age range of 18-50 years old (both inclusive).
- •Should be healthy adult volunteers, with a BMI 18-30 kg/m2 (both inclusive).
- •Volunteer is able to read the volunteer information sheet, to understand information about the study and willing to sign the informed consent voluntarily.
- •Healthy as determined by pre-study medical history, physical examination, vital signs, haematology, chemistry parameters, pulse rate and/or blood pressure, and ECG within the reference range, or showing no clinically relevant deviations, as judged by the Investigator.
- •Negative tests for Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) and human immunodeficiency virus (HIV)-l and HIV -2 antibody at screening.
- •Clinical laboratory test results clinically acceptable at screening and admission.
- •Negative screen for alcohol and drugs of abuse at screening and admission.
- •Non-smokers or ex-smokers (must have ceased smoking >12 months prior screening visit). If a former smoker, reason for stopping smoking to be investigated.
- •The volunteer must agree to comply with the drawing of blood samples for the PK assessments.
- •The volunteer is willing and able to comply with all testing and requirements defined in the protocol.
- •The volunteer is willing and able to remain at the study site for the duration of the confinement period as per the protocol requirements or if exceeded, on Investigator's discretion, if exceeded and return for the outpatient visit.
- •Woman with no childbearing potential by reason of surgery or at least 1-year post-menopause (Le., 12 months post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing;
- •If of childbearing potential, using an effective nonhormonal method of contraception· (intrauterine device or intrauterine system; condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he is the sole partner of that volunteer) for all the duration of the study and up to one month after the last Investigational medicinal product (IMP) administration;
- •Negative serum pregnancy test at screening and negative urine pregnancy test on admission of each treatment period (women of childbearing potential only);
- •Using an effective method of contraception (condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomy) throughout the study and up to one month after the last IMP administration
排除标准
- •Volunteers meeting any of the following criteria will be excluded from this clinical study:
- •The volunteer has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the Investigator.
- •The volunteer has had a clinically significant illness or conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs, within 30 days of Check-in for the study.
- •The volunteer has a clinically relevant history or presence of significant respiratory, neurological, hepatic, renal, endocrine, cardiovascular, neurological, gastrointestinal, pulmonary, haematological, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue, lymphatic or metabolic disease or disorders.
- •The volunteer has a significant infection or known inflammatory process on screening or admission.
- •The volunteer has acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission.
- •The volunteer has a clinically significant surgical history
- •The volunteer has used any prescription medication within 14 days of dosing or over-the-counter (OTC) medication within 48 h of dosing or intends to use any prescription medication or OTC medication during the study that may interfere with the evaluation of study medication.
- •The volunteer has had used medicines within 2 weeks of admission that may affect the safety or other study assessments, in the investigator's opinion
- •The volunteer has consumed alcohol, caffeine or xanthine-containing products 48 h before dosing or intends to use any of these products during the study.
- •The volunteer has consumed grapefruit, grapefruit juice, or grapefruit-containing products 7 days before dosing or intends to use any of these products during the study.
- •The volunteer has a history of substance abuse or a positive ethanol breath test, urine cotinine, or urine drug screen at screening or at check-in.
- •The volunteer has a positive HIV test at the Screening Visit.
- •The volunteer has received an investigational drug within 30 days of Check-in.
- •Use of any investigational drug within 30 days, or 5 half-lives, whichever is longer, prior to the planned first drug administration.
- •The volunteer has participated in more than 2 clinical studies within the 12 months prior to screening.
- •The volunteer has used any investigational drug or participated in any clinical trial within 90 days prior to dosing in this study.
- •The volunteer has donated or lost a significant volume of blood (>450 mL) within 4 weeks prior to the study.
- •The volunteers have a history of hyperemesis
- •The volunteer is unwilling to reside in the study site for the duration of the study or to cooperate fully with the investigator or site personnel.
- •The volunteer has an AST/ALT or total bilirubin greater than the ULN. One repeat test will be allowed.
- •The volunteer has a history of relevant atopy or drug hypersensitivity or known intolerance to the inactive ingredients in the IMP.
- •The volunteer has clinically relevant abnormalities found in physical examination, vital signs measurements, laboratory safety tests or ECG, e.g. QTc according to Bazett: QTc > 450ms, PQ > 220ms, QRS > 120ms
- •The volunteer has supine pulse rate not within 45 to 90 beats per minute and/or supine blood pressure Systolic < 90 >145 mmHg and diastolic < 40 > 95 mmHg.
- •Surgery or trauma with significant blood loss within 2 months before the planned screening for the trial.
- •Any social and medical condition that would jeopardize the volunteer's appropriate participation in this study.
- •Have any medical dietary restrictions.
- •Cannot communicate reliably with the Investigator(s)
- •Are unlikely to co-operate with the requirements of the study.
- •Known or suspected of not being able to comply with the trial protocol and/or clinical unit restrictions.
- •Are unwilling or unable to give written informed consent.
- •Volunteer is an employee of the Sponsor, the Investigator or the Institution of the Investigator.
- •Pregnancy or breast-feeding.
- •Woman of childbearing potential not using an accepted effective contraceptive method or using oral contraceptives
- •Not using an accepted effective method of contraception.
研究组 & 干预措施
MSP008-22
MSP008-22 is a New Chemical Entity (NCE) that has demonstrated positive outcomes during in vitro and in vivo studies for COVID19.
Formulated as tablets intended for oral dosing to trial participants.
干预措施: MSP008-22 (Drug)
Placebo
placebo will be identical in smell, taste, and appearance to the tablets of MSP008-22
干预措施: Placebo (Other)
结局指标
主要结局
Number of participants with adverse events [Time Frame- ]
时间窗: 30 days post last dose for each cohort
To assess safety \& tolerability of MSP008-22 in Human
Percentage of volunteers who meet the markedly abnormal criteria for safety laboratory tests at least once post dose.
时间窗: 7 days post last dose for each cohort
To assess safety MSP008-22 in Human
Percentage of volunteers who experience at least 1 Treatment Emergent Adverse Event (TEAE)
时间窗: 30 days post last dose for each cohort
To assess safety \& tolerability of MSP008-22 in Human
Incidence of serious adverse events (SAEs) by relation to the IMP (related/not related)
时间窗: 30 days post last dose for each cohort
To assess safety \& tolerability of MSP008-22 in Human
Percentage of volunteers who discontinue due to an Adverse Event (AE).
时间窗: 30 days post last dose for each cohort
To assess safety \& tolerability of MSP008-22 in Human
Percentage of volunteers who meet the markedly abnormal criteria for safety electrocardiogram (ECG) parameters at least once post dose.
时间窗: 7 days post last dose for each cohort
To assess safety MSP008-22 in Human
Percentage of volunteers who meet the markedly abnormal criteria for vital sign measurements at least once post dose
时间窗: 7 days post last dose for each cohort
To assess safety MSP008-22 in Human
次要结局
- Plasma AUC0-t(post dose on day 7 in Multiple ascending dose part of the trial)
- Plasma t1/2(in Single ascending Dose trial & post dose on day 7 in Multiple ascending dose part of the trial)
- Plasma Ctrough(on days 2 & 6 in Multiple ascending dose part of the trial)
- Plasma Kel(in Single ascending Dose trial & post-dose on day 7 in Multiple ascending dose part of the trial)
- Plasma AUC0-inf(Single ascending Dose)
- Plasma Tmax(post-dose in Single ascending Dose trial & post dose on days 1 & 7 in Multiple ascending dose part of the trial)
- Plasma Cmax(post-dose in Single ascending Dose trial & post dose on days 1 & 7 in Multiple ascending dose part of the trial)
- Plasma AUC0-tau(post dose on days 1 & 7 in Multiple ascending dose part of the trial)
- Plasma Racc(post dose on days 1 & 7 in Multiple ascending dose part of the trial)
- Plasma AUC0-t(Single ascending Dose)